Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Br J Cancer. 2019 Jan;120(2):139-140. doi: 10.1038/s41416-018-0353-x. Epub 2018 Dec 11.
Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.
免疫检查点抑制剂在多种癌症类型中显示出前所未有的临床活性，但仅在一部分患者中。已经证明检查点抑制剂与其他药物和/或化疗或放疗之间具有有前途的体内协同作用，现在需要有效的模型来选择最佳的联合治疗方案和疾病治疗环境。
